Quarterly report pursuant to Section 13 or 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Aug. 19, 2021
Aug. 09, 2021
Oct. 31, 2021
Oct. 31, 2020
Oct. 31, 2021
Oct. 31, 2020
Apr. 30, 2021
Intangible assets     $ 3,549,427   $ 3,549,427   $ 3,549,427
Impairment of intangible assets         0 $ 0  
Research and development costs     135,220 $ 151,314 278,833 $ 421,888  
Uninsured cash balances     86,658,000   86,658,000   $ 1,921,000
Proceeds from Issuance or Sale of Equity $ 70,000,000 $ 15,000,000          
Deferred offering costs     8,362,137   8,362,137    
Underwriters' fees         7,116,445    
Selling concessions         108,979    
Cell In A Box [Member]              
Intangible assets     1,549,427   1,549,427    
Diabetes License [Member]              
Intangible assets     $ 2,000,000   $ 2,000,000    
S G Austria [Member]              
Percentage investment in SG Austria     14.50%   14.50%